--- title: "Weekly Recap | Merck +0.24%, outperforming the S&P 500 with defensive strength" type: "News" locale: "en" url: "https://longbridge.com/en/news/302173382.md" description: "Merck rose 0.24% this week to close at $145.95, outperforming the S&P 500 by about 2.19 percentage points as the benchmark fell 1.95%. The stock swung 7.38% from high to low in a week that peaked early then faded: Monday closed at $145.45, Tuesday slid to the week’s low of $141.58, Wednesday rebounded 3.81% to $147.37, Thursday touched a high of $152.34 before pulling back to $145.19, and Friday inched up to $145.95. Average daily volume of about 10." datetime: "2026-10-17T07:42:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302173382.md) - [en](https://longbridge.com/en/news/302173382.md) - [zh-HK](https://longbridge.com/zh-HK/news/302173382.md) generator: "portal-rs" --- # Weekly Recap | Merck +0.24%, outperforming the S&P 500 with defensive strength ## The Week Merck rose 0.24% this week to close at $145.95, outperforming the S&P 500 by about 2.19 percentage points as the benchmark fell 1.95%. The stock swung 7.38% from high to low in a week that peaked early then faded: Monday closed at $145.45, Tuesday slid to the week’s low of $141.58, Wednesday rebounded 3.81% to $147.37, Thursday touched a high of $152.34 before pulling back to $145.19, and Friday inched up to $145.95. Average daily volume of about 10.26 million shares ran roughly 19% above the 60-day median, indicating heavier-than-normal turnover. ## Key Events Merck’s news flow split between two fronts this week: eye-disease data and oncology. On Monday, the experimental eye drug met its primary endpoint in a trial, but safety concerns drew cautious analyst commentary. Tuesday brought a cluster of company updates: Phase 3 INTerpath-001 data on intismeran plus Keytruda in resected melanoma at ESMO 2026, election of Paul J. Diaz to the board, and a 12-month price target raised to $157.72. Wednesday evening’s hotter-than-expected CPI print knocked the Nasdaq 100 down 1%, and Thursday’s inflation worries extended the tech sell-off, rotating money into defensive sectors such as pharma; Merck briefly jumped 2% intraday. On Friday, the U.S. biotech sector rose broadly pre-market and at the open, lifting Merck along with peers. No material filings were recorded this week after routine items were filtered out. ## Analyst Ratings Among 27 institutions covering Merck, 14 rate it buy, 5 rate it overweight, and 8 rate it hold; no institution rates it underweight or sell. Aggregated across tiers, 19 institutions assign a buy or overweight rating. The consensus rating is buy, with a consensus target of $158.44, implying roughly 8.56% upside from the latest price. The target range is wide, from $105 on the low end to $186 on the high end, pointing to notable dispersion. Merck ranks 4th out of 203 comparable pharmaceutical companies, placing it near the top of the group. ## The Week Ahead Merck has no earnings or major event scheduled in the coming week. On the macro side, the NAHB housing market index lands on Monday, housing starts and building permits on Tuesday, and weekly EIA crude inventories on Wednesday. The more important date is 29 October, when Merck reports fiscal Q3 2026 results before the open; the market expects EPS of $1.7825 on revenue of $17.3 billion. After this week’s run toward $152 and subsequent fade, that print will serve as the next check on expectations around the eye drug and cancer vaccine pipeline. ## In Short Merck posted a small gain while the S&P 500 dropped 1.95%, underscoring its defensive standing as turnover picked up. Analysts lean constructive with a buy consensus and a target sitting 8.56% above the spot price, though a target range spanning more than $80 reflects disagreement about how quickly the pipeline converts to results. Valuation is elevated at roughly 113x P/E, and the latest session’s money flows were split: large and medium orders turned net buyers while small orders were net sellers. The main event to watch is the 29 October earnings release and how it validates the eye-disease and cancer vaccine narrative. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) ## Related News & Research - [Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%](https://longbridge.com/en/news/302763214.md) - [What Is Merck (MRK) Betting On With Its $2.13 Billion KRAS Deal?](https://longbridge.com/en/news/300416193.md) - [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md) - [GE Vernova Stock Is Taking a Hit – What's Driving the Selloff and What Wall Street Sees Next](https://longbridge.com/en/news/302747785.md) - [U.S. oil exports to Asia plunge as war disrupts shipping, lifting tanker rates to record high](https://longbridge.com/en/news/302792281.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**